Susquehanna International Group, LLP Kodiak Sciences Inc. Call Options Transaction History

Susquehanna International Group, LLP

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	BUY	$4.3 - $9.48 $199,950 - $440,820	46,500 New	46,500 $320,000
Q4 2022 Feb 14, 2023	SELL	$6.52 - $8.05 $1.32 Million - $1.63 Million	-203,100 Reduced 68.99%	91,300 $653,000
Q3 2022 Nov 14, 2022	BUY	$7.57 - $12.5 $1.89 Million - $3.12 Million	249,900 Added 561.57%	294,400 $2.28 Million
Q2 2022 Aug 15, 2022	SELL	$5.04 - $9.48 $284,256 - $534,672	-56,400 Reduced 55.9%	44,500 $340,000
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $136,837 - $1.73 Million	19,300 Added 23.65%	100,900 $779,000
Q4 2021 Feb 14, 2022	BUY	$80.85 - $128.49 $2.7 Million - $4.29 Million	33,400 Added 69.29%	81,600 $6.92 Million
Q3 2021 Nov 15, 2021	BUY	$81.97 - $106.94 $770,518 - $1.01 Million	9,400 Added 24.23%	48,200 $4.63 Million
Q2 2021 Aug 11, 2021	SELL	$77.2 - $126.54 $2.32 Million - $3.8 Million	-30,000 Reduced 43.6%	38,800 $3.61 Million
Q1 2021 May 17, 2021	SELL	$110.45 - $164.47 $7.28 Million - $10.8 Million	-65,900 Reduced 48.92%	68,800 $7.8 Million
Q4 2020 Feb 16, 2021	BUY	$60.78 - $154.03 $6.32 Million - $16 Million	103,900 Added 337.34%	134,700 $19.8 Million
Q3 2020 Nov 16, 2020	BUY	$45.05 - $59.27 $99,110 - $130,394	2,200 Added 7.69%	30,800 $1.82 Million
Q2 2020 Aug 14, 2020	SELL	$42.74 - $66.25 $1.19 Million - $1.85 Million	-27,900 Reduced 49.38%	28,600 $1.55 Million
Q1 2020 May 15, 2020	SELL	$38.18 - $73.95 $5.12 Million - $9.91 Million	-134,000 Reduced 70.34%	56,500 $2.7 Million
Q4 2019 Feb 14, 2020	BUY	$13.9 - $76.65 $2.65 Million - $14.6 Million	190,500 New	190,500 $13.7 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $288M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.